Friday, October 31, 2014 Last update: 3:03 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Day Two of the 2014 BIO International Convention to Feature Sir Richard Branson's First-Hand Account of His Achievements in Over Forty Years of Business, A Vision for New Paradigms in Oncology, Positi

Companies mentioned in this article: Biotechnology Industry Organization

SAN DIEGO -- (BUSINESS WIRE) -- The 2014 BIO International Convention, the world’s largest biotechnology event, kicked off yesterday at the San Diego Convention Center and goes through Thursday, June 26. Hosted by the Biotechnology Industry Organization, this year’s event is expected to attract more than 3,000 biotechnology companies and more than 15,000 attendees from 48 states and 65 countries.

A new website has been created for journalists with photos of the Convention which may be used in print, broadcast or online stories.

Upcoming Convention Highlights Include:

  • Keynote Luncheon: Sir Richard Branson, Founder, Virgin Group, Tuesday, June 24
    Please note: This Keynote session is open to attendees who have registered as Convention Access or higher as well as credentialed members of the print media only. No cameras are allowed in the event.
  • Keynote Luncheon: Hillary Rodham Clinton, Former Secretary of State, Wednesday, June 25
    Media Coverage: The event is open to the press. All members of the media who attend the event must check in – and be provided credentials at Media Registration. Names and IDs will be checked. Seating for print media is limited. Once designated seating is full, media will be directed to an overflow room.
    Media entrance: Media may enter at the D/E entrances.
    Live Truck Pre-Set: 8:00 AM PDT
    Live truck parking: Satellite trucks may park/stage in front of the East Loading Dock (D/E), Convention Way.
    IMPORTANT NOTE: All live trucks must RSVP and request space to gain access. Space is limited and early RSVPs are encouraged.
    RSVP by 5:00 PM PDT, Tuesday, June 24 to Abigail Hirsch, ahirsch@bio.org.
    Cable run: 150 feet
    Smart City is able to accommodate fiber and standard cabling.
    Smart City may be reached at: rhancock@smartcity.com or 619.525.5524.
    Broadcast Pre-Set: 9:30 AM PDT *Note the change in broadcast pre-set time
    IMPORTANT NOTE: Space for cameras is limited. Those planning on covering Secretary Clinton’s remarks must RSVP to gain access. RSVP by 5:00 PM PDT, Tuesday, June 24 to Abigail Hirsch, ahirsch@bio.org.
    Still Photography Pre-Set: 11:00 AM PDT
    IMPORTANT NOTE: Those bringing still cameras will be escorted to set location. All photographs will be captured within the first five minutes of the Keynote. RSVP by 5:00 PM PDT, Tuesday, June 24 to Abigail Hirsch, ahirsch@bio.org.
  • Biofuels & Renewable Chemicals Forum Keynote Address: National Security – Why We Need Industrial Biotech, Tuesday, June 24
    Dennis McGinn, Asst. Secretary, U.S. Navy, Energy, Installations and Environment will speak about industrial biotechnology and national security.
    IMPORTANT NOTE: Mr. McGinn will be available for media questions at 10:30 AM PDT in room 27A.
  • Super Session: A New Paradigm in Oncology Treatment, Tuesday, June 24
    Panelists will discuss the dramatic scientific innovation taking place and a vision for new paradigms in oncology through continued scientific investigation, use of new technologies and innovative collaborations.
  • The BIO/Battelle State Initiatives Report 2014: The Impact of the Biosciences in State Economic Vitality, Tuesday, June 24
    This year’s BIO/Battelle State Initiatives Report describes the size, scope and performance of the bioscience industry sector at the national, state and metro level and reports on trends in state bioscience industry development efforts. A panel of state Governors will examine in detail a series of key performance metrics and discuss state policies and programs designed to accelerate the growth of the biosciences. The discussion panel will provide an analysis on where the industry stands today and how states can continue fostering a bioscience economy in challenging economic times. This report continues to be a national benchmark for examining the trends in job creation and economic vitality of the biosciences industry – health, agriculture, industrial – in the 50 states, District of Columbia, and Puerto Rico.
  • BioTech Primer: Top 10 Current Science Trends, Issues and Advances, Tuesday, June 24
    As investment in new technologies continues to grow, we can expect 2014 to be another showcase year for exciting biotech innovations. Progress in stratified medicine, genomic control and mobile medical technology are changing the way medicine is practiced. Breakthroughs and continuing clinical development in stem cell therapy are bringing us closer to the era of regenerative medicine. Biofuels and industrial enzymes promise to free us from dependence on fossil fuels and lessen our carbon imprint. All of these advances require and are enabled by collaboration between experts from diverse fields. Learn about the most exciting advances of the past year from the experts who translate today’s breakthroughs for the non-scientist professional.
  • Ensuring the Safety and Commercial Success of Biosimilars in the United States, Tuesday, June 24
    With the forthcoming introduction of biosimilars to the U.S. market, there is debate over the approaches that FDA and industry should take to ensure patient safety while promoting market competition and continued biomedical innovation. This session will explore critical issues related to safety, naming and traceability, substitution, product drift, comparability and similarity of biologic medicines, and examine lessons from Europe and other regions of the world with a focus on the launch of the new class of biosimilar monoclonal antibodies (Mabs) in the European market and appropriate responses to safety signals that could emerge.
  • Irreconcilable Differences? A Balanced Approach to Establishing Value, Tuesday, June 24
    Today industry sponsors face two very different criteria for evidence between regulatory bodies and payers. Regulators, such as FDA and EMA, require that clinical studies provide internally consistent evidence establishing efficacy and safety, whereas reimbursement authorities typically focus on whether those data demonstrate external value to the overall healthcare system. No one study can currently meet the needs of these competing audiences, however, a more balanced approach would leverage research activities conducted in parallel to the clinical trial program and linked through endpoints. These endpoints would define patient archetypes within the healthcare system and how they predict healthcare utilization and value. This balanced approach to evidence development can address the needs of reimbursement authorities while reducing the complexity, expense and time to complete studies and thereby decrease the risk to sponsor and authority. This session will discuss how this approach could be implemented and shape ongoing dialog with reimbursement authorities during the development process.
  • View from Director General Francis Gurry, World Intellectual Property Organization, Tuesday, June 24
    Director General Francis Gurry will discuss WIPO activities and their impact on the biotechnology sector.
  • Executives Perspective - 2014: Biofuels and Renewable Chemicals in the Balance?, Tuesday, June 24
    BIO IES board members reflect on the 2014 transformation of the industrial biotech sector from pre-commercial promise to market threat – and the unprecedented policy challenges that have accompanied this transition.
  • Is Value in the Eye of the Beholder?, Tuesday, June 24
    Early stage, pre-clinical assets can prove challenging when it comes to determining the value of a particular product or technology. As deals move to earlier stages of development, how do investors approach the valuation of early stage pre-clinical trial assets? Is there a difference between theory and what is practical or achievable? Can you separate intrinsic value from extrinsic competitive value outside your control? Is it possible to find a “win-win” combination so each party can optimize its outcome? This panel will discuss the strategic and economic factors in collaborations, including what unique aspects of products or early stage technology should be considered when pricing transactions. Panelists will offer insight into what to expect and how to weight valuation questions for both emerging companies and larger partners.
  • Sustaining a Model for Growth of Orphan Products in a Post-ACA World, Tuesday, June 24
    The Affordable Care Act has the potential to expand health insurance coverage to millions of individuals, but whether coverage will translate to timely and robust access to care depends on a number of factors, including implementation of the law’s signature health insurance Exchanges. More than 6 months after the first enrollees were eligible to begin receiving care through the Exchanges, this panel will examine access, coverage and reimbursement trends for therapies and specialty care for orphan diseases. Experts will analyze the environment under ACA and provide their perspective on what this law means for the orphan disease patient community and stakeholders in the drug development ecosystem.
  • Show Me the Outcomes! Delivering Therapeutic Outcomes that Matter for Optimized Pricing, Reimbursement and Market Access, Tuesday, June 24
    No one questions the need to prove value-for-money. But questions remain about the kinds of proof required. The answers vary based on the stakeholders (patients, accountable care organizations or traditional payors, etc.) and therapeutic area (orphan disease or a widespread chronic condition like diabetes). This panel will discuss cases where conventional pharmaceutical wisdom didn't apply. Panelists will compare evidence that has supported past reimbursement decisions and what may be needed in the future, as well as the impact of the changing reimbursement landscape on market access strategies.
  • Reimbursement Considerations for Early-Stage Companies, Tuesday, June 24
    Early-stage companies often have limited funds to develop their product. With their focus on regulatory submission, companies often overlook the changing reimbursement environment and don't think about reimbursement requirements early enough. Investors need reassurance that the product under development will be included on managed care formularies when it reaches the market. With payors increasingly requiring evidence demonstrating the economic and clinical value of a product, more data needs to be collected earlier in development to support reimbursement. How can companies allocate their scarce resources between these competing needs? How much evidence of likely reimbursement do investors and potential pharmaceutical partners need when assessing early-stage products? This session will provide guidance for making sense of this evolving reimbursement environment.
  • BioTech Primer: Top 10 Current Science Trends, Issues and Advances, Tuesday, June 24
    As investment in new technologies continues to grow, we can expect 2014 to be another showcase year for exciting biotech innovations. Progress in stratified medicine, genomic control, and mobile medical technology are changing the way medicine is practiced. Breakthroughs and continuing clinical development in stem cell therapy is bringing us closer to the era of regenerative medicine. Biofuels and industrial enzymes promise to free us from dependence on fossil fuels and lessen our carbon imprint. All of these advances require and are enabled by collaboration between experts from diverse fields. Learn about the most exciting advances of the past year from the experts who translate today’s breakthroughs for the non-scientist professional.
  • Surf's Up – Algae, Marine Biotech and Synthetic Biology are Riding a New Wave of Industrial Biotech in Southern California, Tuesday, June 24
    San Diego has become a major hub of industrial biotech innovation. Leading SoCal industrial biotech innovators highlight the advances coming out of the region’s research institutions and cutting-edge companies.

Day One Session Highlights Included:

  • International BioGENEius Challenge
    The International BioGENEius Challenge promotes excellence and enables students to continue research in biotechnology and design an original independent research project. This year’s finalists will showcase their research in all-day sessions on days one and two of the Convention, and the winners will be announced at Tuesday Keynote Luncheon.
  • The Bioethics of Drug Development – You Make the Call!
    Moderator Steve Usdin of BioCentury led this interactive discussion centered on a hypothetical case study of bringing a molecule from the research phase to marketing and beyond. Speakers focused on the three major development milestones of pre-clinical development, clinical development and regulatory approval, and post-regulatory activities, exploring examples where development and ethics intersect, including human subject protections, expanded access, and pricing. The session included a panel discussion and audience participation, which having the audience play a role much like a company board of directors.
  • Nature Conference on Genomic Technologies and Biomaterials for Understanding Disease
    Speakers at the conference explored how technology advances in sequencing, single-cell analysis, immunotherapy, cell reprogramming and biomaterials are being applied in the context of diverse diseases, including cancer, infectious disease, immune dysfunction and neurodegenerative disorders. The past decade has seen tremendous progress in the use of genome technologies for the detection and interpretation of complex biological processes and for understanding the molecular basis of disease. Speakers focused on how these developments are enabling new approaches to the diagnosis and treatment of a wide array of pathologic conditions. Research on biomaterials offers innovative strategies for translating this knowledge to the clinic.
  • BioTech Primer: The Science Driving Biotech Healthcare
    The Science Driving Biotech Healthcare was a one-day, fast-paced BIO2014 associated course that explained the basic science used to create biotech healthcare products. Using company and product-specific examples, industry experts explained the science that drives research, innovation and drug discovery for the non-scientist professional. From the bench to the bedside, participants learned the science of healthcare and communicate more effectively with colleagues and stakeholders in the rapidly changing healthcare landscape.

Follow the 2014 Convention @BIOConvention, and join the conversation @IAmBIOtech.

Media registration is open from 7:00am – 6:30pm at the San Diego Convention Center. The Convention program features more than 160 sessions in 8 breakout sessions and 9 specialty forums. The majority of attendees, 70 percent, are c-level executives. They split evenly from large companies of 500 or more employees and small companies of 50 employees or less.

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on major trends affecting the industry. The Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. Visit http://convention.bio.org/program/ for the most up-to-date program and speaker information.

The Convention also features the BIO Business Forum, which has grown over the past thirteen years to become the industry's largest partnering event. This year’s Convention is set to break all previous partnering records, with over 28,000 meetings expected to take place. Powered by BIO's One-on-One Partnering™ System, the BIO Business Forum™ fosters the opportunity for companies to initiate business contacts in a friendly environment and schedule private meetings prior to the Convention.

Upcoming BIO Events

BIO Latin America Conference
September 9-11, 2014
Rio de Janeiro, Brazil

Livestock Biotech Summit
September 16-18, 2014
Sioux Falls, SD

BIO Investor Forum
October 7-8, 2014
San Francisco, CA

Pacific Rim Summit on Industrial Biotechnology & Bioenergy
December 7-9, 2014
San Diego, CA

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

For more information:
Visit http://www.bio.org
Follow us on Twitter @IAmBiotech
Join us on LinkedIn/MyBio
Become a fan at facebook.com/IAmBiotech


Copyright © Business Wire 2014
Contact:

Biotechnology Industry Organization
Abigail Hirsch, 202-962-9235
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech